This data indicates that either both treatments, the silencing of p190RhoGAP in cancer cells and the inactivation of p110δ PI3K in macrophages or only the one arm of this combined treatment affects the expression of ATX in tumours. Here, ARHGAP35 is linked to neoplasm.